Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

February 28, 2017

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG

G-202

G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression

Trial Locations (1)

University of Texas Health Science Center, Houston, Houston